Cinciripini PM, Green CE, Shete S, et al. JAMA. 2024;331:1722-1731. 38696203.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.7326/ANNALS-24-01842-JC | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A randomized trial for combination nicotine replacement therapy for smoking cessation among people with HIV in a low-resourced setting.
AIDS
December 2024
School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Objective: The purpose of this study was to evaluate the efficacy of combination nicotine replacement therapy (c-NRT) for smoking cessation among people with HIV (PWH) in South Africa.
Design: We conducted an open label, individually randomized clinical trial.
Methods: Using a two-armed approach, PWH who smoke were randomized to receive either 1) intensive anti-smoking behavioral counseling (BC) or 2) intensive anti-smoking BC plus c-NRT (nicotine patches augmented by nicotine gum).
Avoiding prostate bed radiation for the PSMA-PET detected nodal recurrence patient post prostatectomy.
Clin Transl Radiat Oncol
January 2025
Northern Sydney Cancer Centre, Radiation Oncology Unit, Royal North Shore Hospital, St Leonards, Sydney, NSW, Australia.
Background: Nodal only recurrence post radical prostatectomy (RP) is increasingly recognised in the PSMA scan era. Management is controversial with a curative approach usually incorporating prostate bed and nodal irradiation (PB + NRT) in combination with long-term hormonal therapy. It is unknown whether omitting prostate-bed irradiation (PBRT) is safe in a subgroup of these patients.
View Article and Find Full Text PDFEffects of Varenicline, Bupropion, Nicotine Patch, and Placebo on Treating Smoking Among Persons With Current or Past Major Depressive Disorder: Secondary Analysis of a Double-Blind, Randomized, Placebo-Controlled Trial.
Am J Psychiatry
December 2024
Department of Behavioral Science, University of Texas MD Anderson Cancer Center, Houston (Kypriotakis, Cinciripini, Minnix, Beneventi, Karam-Hage, Blalock); Department of Pediatrics, University of Texas Medical School at Houston (Green); Pfizer Inc., New York (Lawrence); Department of Psychiatry, University of California, San Diego, La Jolla (Anthenelli); Department of Psychiatry, University of Colorado, Aurora (Morris).
Objective: The aim of this study was to compare the safety and efficacy of the leading smoking cessation medications among individuals with current versus past major depressive disorder (MDD).
Methods: This was a secondary analysis of a randomized, double-blind trial over 12 weeks with varenicline or bupropion, followed by a 12-week assessment, in participants ages 18-75 with past (N=2,174) or current (N=451) MDD or without psychiatric disorders (N=4,028). Interventions included 12 weeks of pharmacotherapy with placebo, nicotine replacement therapy (NRT; nicotine patch), bupropion, or varenicline, and brief counseling.
Personalized and adaptive interventions for smoking cessation: Emerging trends and determinants of efficacy.
iScience
November 2024
Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
Article Synopsis
- * Various smoking cessation methods exist, including nicotine replacement therapies and medications like varenicline and bupropion, with new options like cytisine and faster-acting NRTs being developed, enhancing choices for those trying to quit.
- * Personalizing cessation strategies by assessing individual responses and preferences can lead to more effective treatment outcomes, including the potential use of combination therapies for those who need additional support.
Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity.
Neoplasia
January 2025
Department of Respiratory and Critical Care Medicine, the First Affiliated Hospital of Second Military Medical University, Shanghai, 200433, PR China; Center of Critical Care Medicine, the First Affiliated Hospital of Second Military Medical University, Shanghai, 200433, PR China. Electronic address:
Background: The neoantigen vaccine has remarkable potential in treating advanced cancer due to its tumor specificity and ability to bypass central tolerance mechanisms. However, numerous neoantigens show poor immunogenicity, and the immune inhibitory factors of present in both tumors and tumor-draining lymph nodes impair the efficacy of cancer neoantigen vaccine. Eliminating immunosuppressive cells will improve the priming and expansion of anti-tumor immune cells induced by the vaccine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!